De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring

Affiliations

¹ CIC 1436, Team Pharmacologie en Population, Cohortes et Biobanques, and.
² Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
³ Department of Internal Medicine, Adult Immune Cytopenias, Henry Mondor Hospital, Assistance Publique Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
⁴ Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
⁵ Centre of Pharmacovigilance, Rouen University Hospital, Rouen, France.
⁶ Regional Pharmacovigilance Center, Besançon University Hospital, Besançon, France.
⁷ Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.
⁸ Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France.
⁹ Department of Medical Pharmacology, Centre of Pharmacovigilance, Bordeaux University Hospital, Bordeaux, France; and.
¹⁰ INSERM, BPH, U1219, Team Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.

Guillaume Moulis et al. Blood. 2022.

. 2022 Apr 21;139(16):2561-2565.

doi: 10.1182/blood.2022015470.

¹ CIC 1436, Team Pharmacologie en Population, Cohortes et Biobanques, and.
² Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
³ Department of Internal Medicine, Adult Immune Cytopenias, Henry Mondor Hospital, Assistance Publique Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
⁴ Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
⁵ Centre of Pharmacovigilance, Rouen University Hospital, Rouen, France.
⁶ Regional Pharmacovigilance Center, Besançon University Hospital, Besançon, France.
⁷ Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.
⁸ Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France.
⁹ Department of Medical Pharmacology, Centre of Pharmacovigilance, Bordeaux University Hospital, Bordeaux, France; and.
¹⁰ INSERM, BPH, U1219, Team Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.

No abstract available

References

1. Mahévas M, Moulis G, Andres E, et al. . Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4):e224-e229. - PMC - PubMed
1. Lee E-J, Cines DB, Gernsheimer T, et al. . Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021; 96(5):534-537. - PMC - PubMed
1. Lee E-J, Beltrami Moreira M, Al-Samkari H, et al. . SARS-CoV-2 vaccination and immune thrombocytopenia in de novo and pre-existing ITP patients. Blood. 2021;139(10):1564-1574. - PMC - PubMed
1. Choi PY-I, Hsu D, Tran HA, et al. . Immune thrombocytopenia following vaccination during the COVID-19 pandemic [published online ahead of print 26 August 2021]. Haematologica. - PMC - PubMed
1. Gordon SF, Clothier HJ, Morgan H, et al. ; SAEFVIC and VicSIS investigators . Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. Vaccine. 2021;39(48):7052-7057. - PMC - PubMed